Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Dasatinib

EU orphan designation number: EU/3/05/338   
Active ingredient: Dasatinib
Indication: Treatment of acute lymphoblastic leukaemia
Sponsor: Bristol-Myers Squibb Pharma EEIG
Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Sprycel on 20/11/2006 with the number EU/1/06/363

   Public summary of scientific opinion     EPAR

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
03/01/2006 Centralised Orphan - Designation EMEA/OD/074/05 (2005)5969 of 23/12/2005